Mar 6, 2023 • 8:00 am EST Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA
Mar 2, 2023 • 8:00 am EST Corbus Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
Feb 13, 2023 • 6:55 am EST Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)
Nov 10, 2022 • 9:05 am EST Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Nov 8, 2022 • 8:05 am EST Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Oct 14, 2022 • 8:05 am EDT Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Sep 22, 2022 • 8:00 am EDT Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference
Sep 12, 2022 • 7:00 am EDT Corbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 9, 2022 • 8:00 am EDT Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update